NOXOPHARM-LIMITED
18.3.2021 13:02:04 CET | Business Wire | Press release
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clinicians.
Part 1 of the NOXCOVID-1 trial involved 26 patients and was a dose-escalation arm testing the safety of increasing (400, 600, 800, 1200, 1800 mg) daily Veyonda dosages. The 1800 mg dose was deemed to be sufficiently well tolerated in patients with moderate COVID-19 disease to become the preferred dose. The high tolerance of the drug by patients with very poor lung function provides further evidence of the safety of Veyonda in patients with acute illness.
Noxopharm CEO Dr. Graham Kelly said, “The high potency of Veyonda in blocking cytokine release from damaged tissue in the laboratory meant we were obliged to adopt a very cautious and methodical approach when being used for the first time in patients with poor lung function. We can now be confident that Veyonda, despite its potency, is well tolerated at a dosage we believe will be therapeutic.”
Part 2 of the NOXCOVID-1 trial now is starting to recruit a minimum of 10 and up to 15 patients with moderate-to-severe lung dysfunction. Patients will be treated for up to 14 days with an 1800 mg Veyonda dose each day.
Noxopharm is committed to pursuing its NOXCOVID program for two main reasons: Despite the advent of COVID-19 vaccines, emerging news of new mutant strains of the virus points to a likely ongoing long-term need for effective treatments for COVID-19 patients who go on to develop long-term lung damage and are at high risk of septic shock.
The current pandemic represents a small proportion of patients who die each year from septic shock. Even once the pandemic abates, the need for an effective and safe ongoing treatment for septic shock will remain.
About Noxopharm
Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda and is the major shareholder in the nononcology drug development company, Nyrada Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GetVocal Introduces Control Center to Help Enterprises Scale AI Across 90 Percent Plus of Customer Conversations31.3.2026 13:00:00 CEST | Press release
New governance layer enables human-in-the-loop operations, allowing AI to handle customer interactions while humans stay in control of critical decisions GetVocal, Europe’s leading provider of conversational AI agents for enterprise customer support, today announced the launch of its Control Center, a human-AI operations interface designed to help enterprises scale customer experience (CX) automation while maintaining trust, compliance, and full human oversight. As organizations expand AI from simple requests to complex customer journeys, they face a dual operational challenge: if AI acts alone, risk increases; but if humans review everything, automation doesn’t scale. GetVocal’s Control Center solves this challenge by introducing a governance layer for real-time two-way human-AI collaboration. In this hybrid workforce model, AI resolves most customer interactions independently, and humans step in only when judgment, validation, or exception handling is required. The Control Center is
Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code31.3.2026 13:00:00 CEST | Press release
New AI-platform enables non-tech teams to build fully functional, secure applications for real business operations, not just prototypes Softr today evolved into an AI-native platform, marking the end of the AI prototype era and the beginning of production-ready business software that non-technical teams can build, own, and maintain with AI — without writing a single line of code. With the introduction of its new AI Co-Builder, Softr enables teams to replace spreadsheets and manual workflows with secure, fully-functional business applications, including internal tools, customer portals, partner platforms, and operational systems, simply by describing what they need. This milestone marks a major evolution for Softr, a leading player in the no-code software category over the past five years. Since launching in 2020, the company has grown to support more than 1 million builders and 7,000 organizations, including Netflix, Google, Stripe, UPS, and Clay. Softr’s new platform was built to brid
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform31.3.2026 12:00:00 CEST | Press release
Round Led by Collaborative Fund with Participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Cristiano Ronaldo, LeBron James, Rory McIlroy WHOOP, the human performance company, today announced it has raised $575 million in Series G funding at a $10.1 billion valuation, advancing its global expansion and long-term vision for personalized health. The round was led by Collaborative Fund and includes global participation from 2PointZero Group, Qatar Investment Authority (QIA), Mubadala Investment Company, Abbott, Mayo Clinic, Macquarie Capital (entities administered by Macquarie Capital), Glade Brook, B-Flexion, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures, and Bullhound Capital alongside a group of prominent global athletes and individual investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331399622/en/ WHOOP Raises $575 Million at $10.1 B
Interactive Brokers Launches Crypto-Asset Trading for Individual Investors in the European Economic Area31.3.2026 11:00:00 CEST | Press release
Eligible clients can now trade 11 popular crypto-assets including Bitcoin and Ethereum alongside stocks, options, futures, and more, all from a single, integrated platform Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of crypto-asset trading for eligible individual investors in the EEA through Interactive Brokers Ireland Limited, which is an authorised crypto-asset service provider in the EEA. Many European investors face challenges managing multiple crypto apps, understanding unclear fees, or navigating security concerns. Interactive Brokers now offers a solution. Starting today, eligible individual investors in the EEA can trade 11 leading crypto-assets directly on the same platform they already use for stocks, options, futures, currencies, bonds, and mutual funds. This integrated approach gives clients a unified view of their entire portfolio. With one login, they can manage both traditional and crypto-assets, backed by the control, low p
Philip Morris International Presents its Value Report 2025: change in motion31.3.2026 10:30:00 CEST | Press release
The company’s annual disclosure unveils its Value Plan 2030+ Philip Morris International (NYSE: PM) today released its Value Report 2025, offering a holistic perspective on the company’s approach to sustainable value creation. The report marks the completion of PMI’s 2025 Roadmap, communicating achievements for each aspiration introduced by the company in 2020, and introduces its Value Plan 2030+, set to guide the company’s continued path to sustainable growth. “For more than a decade, PMI has pursued an industry-leading shift away from cigarettes—a transformation that goes far beyond product innovation to encompass how we allocate capital, engage stakeholders, and measure success,” said Jacek Olczak, Group Chief Executive Officer. “‘change in motion’ captures the reality that transformation is not a project with a defined end date, it is the continuous work of improvement, innovation, and adaptation that keeps us relevant and resilient. We transform continuously because markets evolve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom